FDA label
What is voriconazole used for?
The FDA-approved uses of voriconazole, quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for voriconazole (tablet, film coated) lists 5 uses: Invasive Aspergillosis; Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections; Esophageal Candidiasis; Scedosporiosis and Fusariosis; and 1 more.
Run it in Rivvi
Which 2027 plans near you dropped or restricted voriconazole?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Voriconazole, tablet, film coated
Indications and Usage, quoted from the label by Ajanta Pharma USA Inc. (ANDA206181). Cross-references to other label sections are left out.
Invasive Aspergillosis
Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus.
Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections
Voriconazoletablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds.
Esophageal Candidiasis
Voriconazoletablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC).
Scedosporiosis and Fusariosis
Voriconazole tablets are indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani, in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy.
Usage
Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Source: DailyMed label, set id 16a80777-f1f3-45bb-a312-998b07767fe3, version 22, effective April 24, 2026. NDC 27241-062, one of 30 listings for this product.
Voriconazole, injection, powder, lyophilized, for solution
Indications and Usage, quoted from the label by Camber Pharmaceuticals, Inc. (ANDA218533). Cross-references to other label sections are left out.
Invasive Aspergillosis
Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus.
There was a small number of cases of culture-proven disease due to species of Aspergillusother than A. fumigatus.
Candidemia in Non-neutropenic Patients and Other Deep Tissue CandidaInfections
Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candidainfections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds.
Esophageal Candidiasis
Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC).
Scedosporiosis and Fusariosis
Voriconazole for injection is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum(asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani, in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy.
Usage
Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Source: DailyMed label, set id fff10d69-e334-42bd-baed-7d9d5feef6aa, version 3, effective April 13, 2026. NDC 31722-224, one of 10 listings for this product.
Voriconazole, powder, for suspension
Indications and Usage, quoted from the label by Amneal Pharmaceuticals LLC (ANDA205034). Cross-references to other label sections are left out.
Invasive Aspergillosis
Voriconazole for oral suspension is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus.
Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections
Voriconazole for oral suspension is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds.
Esophageal Candidiasis
Voriconazole for oral suspension is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC).
Scedosporiosis and Fusariosis
Voriconazole for oral suspension is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani, in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy.
Usage
Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Source: DailyMed label, set id ed6624a9-0b73-4a21-bf13-a8add2081d02, version 25, effective March 2, 2026. NDC 65162-913, one of 5 listings for this product.
Questions
What is voriconazole used for?
The FDA label for voriconazole (tablet, film coated) lists 5 uses: Invasive Aspergillosis; Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections; Esophageal Candidiasis; Scedosporiosis and Fusariosis; and 1 more.
What drug class is voriconazole?
FDA lists voriconazole in the Azole Antifungal established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.